C S Mathy1,2, T Mayr2, M H Muders3, R A Bundschuh4, S Kürpig1, M Meisenheimer1, R C Dolscheid-Pommerich5, B Stoffel-Wagner5, G Kristiansen2, M Essler1. 1. Department of Nuclear Medicine, University Hospital Bonn, Venusberg Campus 1, 53127, Bonn, Germany. 2. Department of Pathology, University Hospital Bonn, Venusberg Campus 1, 53127, Bonn, Germany. 3. Department of Pathology, University Hospital Bonn, Venusberg Campus 1, 53127, Bonn, Germany. Michael.Muders@ukbonn.de. 4. Department of Nuclear Medicine, University Hospital Bonn, Venusberg Campus 1, 53127, Bonn, Germany. Ralph.Bundschuh@ukbonn.de. 5. Institute of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, Venusberg Campus 1, 53127, Bonn, Germany.
Abstract
BACKGROUND: In recent years, a variety of innovative therapeutics for castration-resistant prostate cancer have been developed, including novel anti-androgenic drugs, such as abiraterone or VPC-13566. Therapeutic monitoring of these pharmaceuticals is performed either by measuring PSA levels in serum or by imaging. PET using PSMA ligands labeled with Fluor-18 or Gallium-68 is the most sensitive and specific imaging modality for detection of metastases in advanced prostate cancer. To date, it remains unclear how PSMA expression is modulated by anti-hormonal treatment and how it correlates with PSA secretion. METHODS: We analyzed modulation of PSMA-mRNA and protein expression, 68Ga-PSMA uptake and regulation of PSA secretion by abiraterone or VPC-13566 in LNCaP cells in vitro. RESULTS: We found that abiraterone and VPC-13566 upregulate PSMA protein and mRNA expression but block PSA secretion in LNCaP cells. Both anti-androgens also enhanced 68Ga-PSMA uptake normalized by the number of cells, whereas abiraterone and VPC-13566 reduced 68Ga-PSMA uptake in total LNCaP monolayers treated due to cell death. CONCLUSION: Our data indicate that PSA secretion and PSMA expression are differentially regulated upon anti-androgen treatment. This finding might be important for the interpretation of 68Ga-PSMA PET images in monitoring therapies with abiraterone and VPC-13566 in prostate cancer patients, but needs to be validated in vivo.
BACKGROUND: In recent years, a variety of innovative therapeutics for castration-resistant prostate cancer have been developed, including novel anti-androgenic drugs, such as abiraterone or VPC-13566. Therapeutic monitoring of these pharmaceuticals is performed either by measuring PSA levels in serum or by imaging. PET using PSMA ligands labeled with Fluor-18 or Gallium-68 is the most sensitive and specific imaging modality for detection of metastases in advanced prostate cancer. To date, it remains unclear how PSMA expression is modulated by anti-hormonal treatment and how it correlates with PSA secretion. METHODS: We analyzed modulation of PSMA-mRNA and protein expression, 68Ga-PSMA uptake and regulation of PSA secretion by abiraterone or VPC-13566 in LNCaP cells in vitro. RESULTS: We found that abiraterone and VPC-13566 upregulate PSMA protein and mRNA expression but block PSA secretion in LNCaP cells. Both anti-androgens also enhanced 68Ga-PSMA uptake normalized by the number of cells, whereas abiraterone and VPC-13566 reduced 68Ga-PSMA uptake in total LNCaP monolayers treated due to cell death. CONCLUSION: Our data indicate that PSA secretion and PSMA expression are differentially regulated upon anti-androgen treatment. This finding might be important for the interpretation of 68Ga-PSMA PET images in monitoring therapies with abiraterone and VPC-13566 in prostate cancerpatients, but needs to be validated in vivo.
Authors: Francesco Ceci; Christian Uprimny; Bernhard Nilica; Llanos Geraldo; Dorota Kendler; Alexander Kroiss; Jasmin Bektic; Wolfgang Horninger; Peter Lukas; Clemens Decristoforo; Paolo Castellucci; Stefano Fanti; Irene J Virgolini Journal: Eur J Nucl Med Mol Imaging Date: 2015-05-15 Impact factor: 9.236
Authors: Hojjat Ahmadzadehfar; Simone Wegen; Anna Yordanova; Rolf Fimmers; Stefan Kürpig; Elisabeth Eppard; Xiao Wei; Carl Schlenkhoff; Stefan Hauser; Markus Essler Journal: Eur J Nucl Med Mol Imaging Date: 2017-05-09 Impact factor: 9.236
Authors: Louise Emmett; Charlotte Yin; Megan Crumbaker; George Hruby; Andrew Kneebone; Richard Epstein; Quoc Nguyen; Adam Hickey; Noah Ihsheish; Gordon O'Neill; Lisa Horvath; Venu Chalasani; Phillip Stricker; Anthony M Joshua Journal: J Nucl Med Date: 2018-12-14 Impact factor: 10.057
Authors: Martina Benešová; Martin Schäfer; Ulrike Bauder-Wüst; Ali Afshar-Oromieh; Clemens Kratochwil; Walter Mier; Uwe Haberkorn; Klaus Kopka; Matthias Eder Journal: J Nucl Med Date: 2015-04-16 Impact factor: 10.057
Authors: Jens Cardinale; Martin Schäfer; Martina Benešová; Ulrike Bauder-Wüst; Karin Leotta; Matthias Eder; Oliver C Neels; Uwe Haberkorn; Frederik L Giesel; Klaus Kopka Journal: J Nucl Med Date: 2016-10-27 Impact factor: 10.057
Authors: Thomas A Hope; Charles Truillet; Eric C Ehman; Ali Afshar-Oromieh; Rahul Aggarwal; Charles J Ryan; Peter R Carroll; Eric J Small; Michael J Evans Journal: J Nucl Med Date: 2016-09-22 Impact factor: 10.057
Authors: Michael S Hofman; Nathan Lawrentschuk; Roslyn J Francis; Colin Tang; Ian Vela; Paul Thomas; Natalie Rutherford; Jarad M Martin; Mark Frydenberg; Ramdave Shakher; Lih-Ming Wong; Kim Taubman; Sze Ting Lee; Edward Hsiao; Paul Roach; Michelle Nottage; Ian Kirkwood; Dickon Hayne; Emma Link; Petra Marusic; Anetta Matera; Alan Herschtal; Amir Iravani; Rodney J Hicks; Scott Williams; Declan G Murphy Journal: Lancet Date: 2020-03-22 Impact factor: 79.321
Authors: Julian M M Rogasch; Frank Hofheinz; Lutz van Heek; Conrad-Amadeus Voltin; Ronald Boellaard; Carsten Kobe Journal: Diagnostics (Basel) Date: 2022-02-10